Last reviewed · How we verify
CV0801 mRNA COVID-19 Vaccine — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
CV0801 mRNA COVID-19 Vaccine (CV0801 mRNA COVID-19 Vaccine) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CV0801 mRNA COVID-19 Vaccine TARGET | CV0801 mRNA COVID-19 Vaccine | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CV0801 mRNA COVID-19 Vaccine CI watch — RSS
- CV0801 mRNA COVID-19 Vaccine CI watch — Atom
- CV0801 mRNA COVID-19 Vaccine CI watch — JSON
- CV0801 mRNA COVID-19 Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). CV0801 mRNA COVID-19 Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/cv0801-mrna-covid-19-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab